Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCXH-213 in Adults With Primary Immune Thrombocytopenia
NCT07622329Phase 1Not yet recruiting
- Sponsor
- General Hospital of Western Theater Command of PLA
- Start
- Jun 2026
- Primary completion
- Aug 2026
01
Overview
Phase 1, open-label, single-arm trial of JCXH-213 in primary immune thrombocytopenia (ITP), sponsored by General Hospital of Western Theater Command of PLA. Primary endpoint: Safety and tolerability of JCXH-213 (DLT observation) at 14 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
JCXH-213
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07622329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622329.